

1 **Title:** Effect of chronic JUUL aerosol inhalation on inflammatory states of the brain, lung, heart and
2 colon in mice

3
4 **One Sentence Summary:** Chronic, daily inhalation of pod-based e-cigarette aerosols alters the
5 inflammatory state across multiple organ systems in mice.

6
7 **Authors:** Alex Moshensky^{a,b,#}, Cameron Brand^{c,#}, Hasan Alhaddad^{d,#}, John Shin^{a,b}, Jorge A. Masso-
8 Silva^{a,b}, Ira Advani^{a,b}, Deepti Gunge^{a,b}, Aditi Sharma^e, Sagar Mehta^{a,b}, Arya Jahan^{a,b}, Sedtavut Nilaad^{a,b},
9 Daniyah Almarghalani^d, Josephine Pham^{a,b}, Samantha Perera^{a,b}, Kenneth Park^{a,b}, Rita Al-Kolla^{a,b},
10 Hoyoung Moon^c, Soumita Das^e, Min Byun^{a,b,f}, Zahoor Shah^g, Youssef Sari^d, Joan Heller Brown^c, and
11 Laura E. Crotty Alexander^{a,b}

12
13 **Affiliations:**

14 ^a Pulmonary and Critical Care Section, VA San Diego Healthcare System, La Jolla, CA 92161

15 ^b Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University
16 of California San Diego (UCSD), La Jolla, CA 92093

17 ^c Department of Pharmacology, UCSD, La Jolla, CA 92093

18 ^d Department of Pharmacology and Experimental Therapeutics,
19 College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH 43614

20 ^e Department of Pathology, UCSD, La Jolla, CA 92093

21 ^f Division of Pulmonology, Department of Internal Medicine, Gangnam Severance Hospital,
22 Yonsei University College of Medicine, Seoul, South Korea

23 ^g Department of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical
24 Sciences, University of Toledo, Toledo, OH 43614

25
26 # These authors contributed equally.

27 * Corresponding Author: Laura E. Crotty Alexander; UCSD 9500 Gilman Dr, MC 9111J, San Diego, CA
28 92093; FAX: 858-646-2802 Phone: 619-438-4207 email: LCA@ucsd.edu

29
30 **Keywords:** JUUL, E-cigarette, vaping, inflammation, lung compliance, airway resistance, nicotine,
31 toxicology

32

33

34

35 **Abstract**

36 While health effects of conventional tobacco are well defined, data on vaping devices, including the most
37 popular e-cigarette JUUL, are less established. Prior acute e-cigarette studies demonstrated inflammatory
38 and cardiopulmonary physiology changes while chronic studies demonstrated extra-pulmonary effects,
39 including neurotransmitter alterations in reward pathways. In this study we investigated effects of chronic
40 flavored JUUL aerosol inhalation on inflammatory markers in brain, lung, heart, and colon. JUUL
41 induced upregulation of cytokine and chemokine gene expression and increased HMGB1 and RAGE in
42 the nucleus accumbens. Inflammatory gene expression increased in colon, and cardiopulmonary
43 inflammatory responses to acute lung injury with lipopolysaccharide were exacerbated in the heart.
44 Flavor-dependent changes in several responses were also observed. Our findings raise concerns regarding
45 long-term risks of e-cigarette use as neuroinflammation may contribute to behavioral changes and mood
46 disorders, while gut inflammation has been tied to poor systemic health and cardiac inflammation to
47 development of heart disease.

48 **Introduction**

49 Chronic inhalation of tobacco smoke is known to damage multiple cell types and cause a wide range of
50 diseases throughout the body. In particular, many pulmonary inflammatory diseases are caused and
51 affected by conventional tobacco use (1, 2). It is also known that nicotine affects brain development and
52 alters responses to addictive substances. Nicotine activates carcinogenic pathways, putting users at an
53 increased risk of cancer (3). With unproven claims to be a safer alternative to cigarette smoking, modern
54 electronic (e)-cigarette devices were introduced in 2003 as a novel nicotine delivery system (4, 5). The
55 JUUL™, a device that gained popularity due to its sleek and concealable design, has utilized pods
56 containing e-liquids with enticing flavors such as Mango, Mint, and Crème Brulee (now discontinued)(6).
57 However, the health effects of chronic inhalation of aerosols generated from pod devices remain largely
58 unknown.

59
60 While the data on health effects of conventional tobacco are extensive, the data on e-cigarettes and vaping
61 devices are less established due to their recent entry to the market (7, 8). In particular, research in this area
62 is impeded by the rapid evolution of vaping devices. The vape pens and cig-a-likes were the first e-
63 cigarettes studied from 2007-2014, whereas the box Mods became highly popular and research on these
64 devices began around 2015. Pod devices, including the JUUL, were invented in 2016 and rapidly
65 dominated the market by 2017-2020, however, studies on the harmful effects of these types of vaping
66 devices are scarce (9). Thus, research on the health effects of these pod-based devices, which produce
67 aerosols with a different chemical composition than prior devices (including often significant higher
68 concentrations of nicotine than Mod devices), is desperately needed.

69
70 Because of the short time e-cigarettes and vaping devices have been on the market, very little is known
71 about the long-term chronic effects of vaping. Acute and subacute studies in human subjects have
72 demonstrated changes in lung and cardiac function, with increased airway reactivity and lung
73 inflammation, and increased heart rate and blood pressure in response to vaping (7). Previous studies of

74 chronic effects of vaping are limited to e-cigarette aerosol inhalation models in animals but have
75 demonstrated more profound effects, including renal, cardiac and liver fibrosis (10), emphysema (11),
76 lung cancer (12), increased lung injury in the setting of influenza infection (13), increased arterial
77 stiffness and atherosclerosis, and activation of addiction neurocircuits in the brain (14, 15).

78

79 The health effects of vaping JUUL pods remain unknown, despite the popularity of pod-based e-devices.
80 Here, we broadly assessed the effects of daily JUUL aerosol inhalation on cardiopulmonary function and
81 inflammation across organ systems, including the reward pathways in the brain. We induced acute lung
82 injury with inhaled *E. coli* lipopolysaccharide (LPS) to determine whether chronic JUUL use predisposes
83 to deleterious responses in the setting of common infectious challenges such as Gram-negative bacterial
84 pneumonia. We demonstrated here that daily inhalation of JUUL aerosols can lead to inflammatory
85 changes in the brain, heart, lung, and colon, as well as alterations in physiological functions.

86

87 **Results**

88 **Chronic JUUL inhalation associated with neuroinflammation in the brain**

89 Previous studies have shown that conventional tobacco smoking increases proinflammatory cytokines in
90 the brain, specifically TNF α , IL-1 β , IL-6 (16, 17). Therefore, gene expression of these inflammatory
91 cytokines were measured by qPCR in different brain regions of mice exposed to JUUL Mango and JUUL
92 Mint, as well as Air controls for 1 or 3 months. Specifically, we assessed gene expression in the nucleus
93 accumbens core and shell (NAc-core and NAc-shell), and hippocampus, regions involved in behavior
94 modification, formation of drug reward and anxious or depressive behaviors, and learning and memory,
95 respectively. We observed that TNF α gene expression was significantly increased in the NAc-core and
96 NAc-shell of mice exposed to 1 or 3 months of JUUL Mango or JUUL Mint compared to Air controls
97 (**Figure 1A-D**). In contrast, TNF α levels were unchanged in the hippocampus throughout the exposures
98 (**Figure 1E-F**). IL-1 β gene expression was also significantly elevated in JUUL Mint- and Mango-exposed
99 mice group in both the NAc-core and NAc-shell at 1 month compared to air control group (Figure 1G and

100 1I), but remained elevated at 3 months only in the NAc-shell (Figure 1J) and not in NAc-core (Figure
101 1H). The hippocampus showed unchanged levels of IL-1 β gene expression at 1 and 3 months across
102 groups (Figure 1K and 1L). In the case of IL-6, we observed a significant increase in gene expression in
103 the NAc-shell in both JUUL Mango and JUUL Mint groups at 1 and 3 months (**Figure 1O and 1P**), but
104 no significant differences were observed in the NAc-core and hippocampus when compared to Air
105 controls (**Figure 1M, 1N, 1Q and 1R**). Overall, these data suggest that exposure to JUUL Mint and
106 JUUL Mango may induce neuroinflammation in brain regions responsible for behavior modification, drug
107 reward and formation of anxious or depressive behaviors (18).

108
109 To further confirm the neuroinflammatory response associated with chronic JUUL exposure, we
110 measured levels of receptors for advanced glycation end products (RAGE) and its ligand high mobility
111 group box 1 (HMGB1) protein by western blot in the NAc-core, NAc-shell, and hippocampus of mice
112 exposed to JUUL Mango, JUUL Mint and Air at 1 and 3 months. RAGE and HMGB1 have been
113 implicated in inducing neuroinflammation (16), and previous studies have shown that HMGB1-1 and
114 RAGE expression are increased with exposure to cigarette smoke (19, 20). No significant changes of
115 HMGB1 were observed in NAc-core at 1 or 3 months of JUUL aerosol exposure between groups (**Figure**
116 **2A-B**). The NAc-shell, however, showed significant increase in HMGB1 at 1 and 3 months in mice
117 exposed to JUUL Mango and JUUL Mint relative to Air controls (**Figure 2C-D**), and the increase was
118 more pronounced at 3 months (**Figure 2D**). The hippocampus showed no changes in HMGB1 protein
119 expression at 1 month (**Figure 2E**), and actually showed significant decrease in protein expression in
120 mice exposed for 3 months to either JUUL Mango or JUUL Mint as compared to Air controls (**Figure**
121 **2F**). In the case of RAGE, the protein levels were not significantly altered in all tested brain regions
122 (**Figure 2G-I, 2K-L**), except in the NAc-shell of the mice exposed to JUUL Mango or JUUL Mint for 3
123 months when compared to Air controls (**Figure 2J**). Altogether, these data indicate that exposure to
124 aerosols from JUUL devices induced neuroinflammation in reward brain regions, particularly that of the
125 NAc-shell and NAc-core regions.

126

127 **Chronic inhalation of JUUL aerosols alters inflammatory and fibrosis associated gene expression in**
128 **cardiac tissue**

129 Changes in the myocardium have been widely observed in response to cigarette smoking, and we
130 previously showed that inhalation of e-cigarette aerosol generated by Vape pens for 3-6 months induced
131 fibrotic changes in cardiac tissue (10). Fibrosis is typically driven by either cellular injury or
132 inflammation. Increases in pro-inflammatory cytokines and fibrosis-associated proteins have been linked
133 to the development of cardiovascular diseases (21-24). Based on the inflammatory and fibrotic markers
134 commonly observed in response to myocardial infarction and development of heart failure, we assessed
135 the expression of mRNA for TNF α , IL-1 β , IL-6, IL-18, CCL2, CCL3, CXCL1, CXCL2, Col1a1, Col3a1,
136 Postn and TLR4 at 1 and 3 months (**Figure 3A-X**). Surprisingly, none of the pro-inflammatory cytokines
137 or chemokines examined were upregulated by JUUL exposure. Indeed, TNF α , IL-6, and CXCL2 were
138 actually down-regulated in 1 month JUUL Mint exposed mice, as was the pro-fibrotic gene Col1a1
139 (**Figure 3A, 3E, 3O and 3Q**). In contrast to JUUL Mint, aerosol inhalation of JUUL Mango for 1 month
140 was only associated with the downregulation of CXCL2 (**Figure 3O**). JUUL Mint and Mango aerosol
141 inhalation also had differing effects on CXCL2 and TLR4 expression at 3 months of exposure (**Figure 3P**
142 **and 3X, respectively**). These findings suggest that there may be flavor-specific effects in addition to
143 nicotine-specific effects on the cardiovascular system. Overall, these changes show that inflammatory
144 pathways in cardiac tissue are affected by JUUL aerosol inhalation. While overt inflammation is not
145 induced, it is well known that any alterations to the immune-inflammation axis, activating or suppressive,
146 can lead to changes in disease susceptibility and incidence (25).

147

148 **Chronic JUUL aerosol inhalation alters pro-inflammatory markers in the colon.**

149 Due to the altered inflammation observed in brain and cardiac tissue, we also assessed inflammation in
150 the colon, where cigarette smoking has been shown to alter inflammation and thereby promote chronic
151 digestive diseases (26, 27). In terms of documenting the effects of e-cigarettes on gastrointestinal

152 inflammation, our knowledge is limited to only the study done by our research group, with a focus on
153 changes induced by aerosols generated by box Mods only (28). In order to assess JUUL induced changes
154 in the gastrointestinal tract, we examined inflammatory gene expression at 1 and 3 months of JUUL
155 exposure. JUUL Mango induced upregulation of TNF α , IL-6, and IL-8 relative to Air controls after 1
156 month exposure (**Figure 4A, 4C, 4G**). Interestingly, at 3 months, JUUL Mango treatment resulted in less
157 expression of TNF α , IL-6 and IL-1 β than that observed in Air controls or JUUL Mint exposed mice
158 (**Figure 4B, 4D, 4F**), but increased expression of CCL2 (**Figure 4J**). These data suggest that exposure to
159 JUUL Mango aerosols modulates inflammation in the colon, primarily inducing key inflammatory
160 cytokines at 1 month. In JUUL Mango and Mint, there was no change in IL-1B or CCL2 at 1 month
161 (**Figure 4E and 4I**) and IL-8 at 3 months (**Figure 4H**).

162

163 **Daily JUUL aerosol inhalation does not alter heart rate and blood pressure.**

164 Chronic exposure to cigarette smoke leads to cardiovascular changes, mediated through altered autonomic
165 tone, but little is known about the chronic cardiovascular effects of e-cigarettes, especially with pod
166 devices (7). Thus, we exposed mice to JUUL aerosols and carried out assessments of cardiovascular
167 function, including blood pressure (BP), heart rate (HR), and heart rate variability (HRV). Heart rate
168 variability was determined from root-mean square differences of successive R-R intervals (RMSSD) and
169 the mean of the standard deviations for all R-R intervals (SDNN). There were no significant changes in
170 HR or HRV at 1 and 3 months of either JUUL Mint or JUUL Mango exposure relative to Air controls
171 (**Supplemental Figure 1**). Similarly, systolic and diastolic BP were also unchanged relative to Air
172 controls at either 1 or 3 months (**Supplemental Figure 1**). Thus, chronic exposure to pod-based e-
173 cigarette aerosols containing high levels of nicotine does not appear to alter normal physiological
174 autonomic cardiovascular regulation in mice.

175

176 **Chronic inhalation of JUUL aerosols does not alter pulmonary physiology**

177 Lungs represent the main site for aerosol deposition during inhalant use. Several studies have shown the
178 effects of e-cigarettes on lung physiology (7, 29). To determine the effect of chronic JUUL aerosol
179 inhalation on lung physiology, mechanic scans of airways resistance and lung elastance were carried out
180 and were found to be similar across JUUL Mint, JUUL Mango and Air control groups at 1 and 3 months
181 of exposure (**Supplemental Figure 2**). Pressure-volume (PV) loops also demonstrated similarities
182 amongst the three groups at 1 and 3 months (**Supplemental Figure 2**). Airway hyperreactivity was tested
183 by methacholine challenge and revealed no differences amongst groups, as measured at 1 and 3 months
184 (**Supplemental Figure 2**). Thus, long-term exposure to JUUL Mint and Mango aerosols does not appear
185 to lead to significant changes in airway physiology.

186

187 **Chronic JUUL inhalation does not change the inflammatory state of lungs under homeostatic** 188 **conditions**

189 Conventional tobacco as well as some e-cigarette aerosol exposures, have been found to cause increased
190 cellularity in the airways (2, 7, 8), and cigarette smoking leads to recruitment of neutrophils to the airways
191 in particular (2). Total leukocyte and neutrophil counts in bronchoalveolar lavage (BAL) of mice exposed
192 to JUUL aerosols for 1 and 3 months were not different than those in Air controls, indicating that
193 inflammatory cell recruitment to the airways was unaffected (**Supplemental Figure 3**). Moreover, fixed
194 lung sections stained with H&E showed no difference in inflammation in the lungs at 1 and 3 months of
195 JUUL aerosol exposure as compared to Air controls (**Supplemental Figure 3**).

196

197 **Chronic JUUL inhalation does not induce cardiac, renal or liver fibrosis**

198 Our previous studies with mice exposed to aerosols generated from Vape pens not only found fibrosis in
199 cardiac tissue after 3-6 months of e-cigarette aerosol inhalation but also in the liver and kidneys (10).
200 Cigarette smoking is also known to cause organ fibrosis (30). There were, however, no significant
201 changes in fibrosis assessed by quantification of collagen fibers stained with Masson's trichrome, in the

202 liver, heart or kidneys of mice that inhaled JUUL Mango or JUUL Mint aerosols for 3 months relative to
203 Air controls (**Supplemental Figure 4**).

204

205 **Impact of JUUL exposure on airway inflammation in the setting of inhaled LPS challenge**

206 Long-term cigarette smoking is known to predispose to greater inflammatory responses to lung infections
207 (2). However, few studies have examined the effects of e-cigarette vaping on the severity of attendant
208 respiratory diseases (13). Under homeostatic conditions, the BAL of JUUL Mango and JUUL Mint mice
209 contains similar levels of inflammatory cytokines and chemokines at both 1 and 3 months (**Figure 5A-N**).
210 Inhaled LPS is a model of Gram-negative bacterial pneumonia and acute lung injury in mice. Mice
211 exposed to JUUL aerosols and challenged with inhaled LPS had similar total numbers of leukocytes and
212 neutrophils in the airways relative to Air controls (**Supplemental Figure 3**), and histological analysis of
213 H&E staining showed that parenchymal inflammation was similar across groups after LPS challenge
214 (**Supplemental Figure 3**). LPS challenge also leads to increased levels of CCL2 and KC (murine
215 homolog of IL-8) in the airways. The increases in CCL2 and KC elicited by LPS were diminished in mice
216 exposed to JUUL Mint, demonstrating an attenuated inflammatory response to LPS after sub-acute
217 exposure to JUUL (**Figure 5A and 5C**, respectively). Differences in LPS induced cytokine levels were no
218 longer observed after 3 month JUUL exposure versus Air control groups (**Figure 5B, 5D, 5F, 5H, 5J, 5L**
219 **and 5N**), suggesting that chronic use of JUUL does not significantly alter inflammatory responses to
220 Gram-negative infections in the lung.

221

222 **Cardiac inflammation induced by inhaled LPS challenge is increased in the setting of chronic** 223 **JUUL aerosol inhalation**

224 Bacterial pneumonia and acute lung injury lead to inflammation not only in the lungs and systemic
225 circulation, but also in the heart (31). It is common for patients to develop myocardial inflammation and
226 even ischemia during lung infections (31, 32). Tobacco smoking is well known to increase cardiovascular
227 diseases and worsen outcomes in the setting of pneumonia (2, 33) and recently, it has been suggested that

228 dual use of e-cigarettes with conventional tobacco leads to significantly higher odds of cardiovascular
229 disease compared with cigarette smoking alone (34). Thus, we assessed the impact of acute lung injury on
230 inflammation in cardiac tissues of JUUL exposed mice.

231
232 We assessed the expression of TNF α , IL-1 β , IL-6, IL-18, CCL2, CCL3, CXCL1, CXCL2, Col1a1,
233 Col3a1, Postn and TLR4 at 1 and 3 months to determine if the LPS challenge caused changes in cardiac
234 inflammation in the setting of JUUL aerosol inhalation (**Figure 6A-X**). LPS challenge of mice exposed
235 to JUUL Mint for 1 month lead to significantly greater expression of cytokines (TNF α , IL-1 β , IL-6) and
236 chemokines (CCL2, CCL3, CXCL1, CXCL2) than observed in Air controls (**Figure 6A, 6C, 6E, 6I, 6K,**
237 **6M, 6O**). The enhanced chemokine induction was sustained and even further elevated after 3 month
238 exposure to JUUL Mint (**Figure 6J, 6L, 6N, 6P**). In contrast to the elevated inflammatory response to
239 LPS observed in mice exposed to JUUL Mint, JUUL Mango exposed mice did not have enhanced
240 expression of cytokines or chemokines compared to Air controls. Indeed, the effects of 1 month JUUL
241 Mint versus JUUL Mango exposure were statistically significant with regard to changes in TNF α , IL-1 β ,
242 IL-18, CCL3, CXCL2 (**Figure 6A, 6B, 6G, 6K, 6M**) as well as on CXCL1 expression at both 1 and 3
243 months JUUL exposure (**Figure 6 M-N**).

244
245 Enhanced inflammatory responses within tissues are known to result in fibrosis in some cases. However,
246 analysis of pro-fibrotic gene expression only revealed that Col3a1 was significantly higher after 3 month
247 JUUL Mint exposure (**Figure 6T**). Col1a1 and TLR4 expression were not higher in the JUUL exposed
248 groups. Indeed, periostin expression was lower in 1 month JUUL Mint and JUUL Mango compared to
249 Air (**Figure 6U**) and TLR4 expression was also lower in the 3 month JUUL Mango group (**Figure 6X**).
250 Thus, while fibrotic changes are not evident, the enhanced expression of chemokines and cytokines
251 indicates that the use of JUUL devices could predispose to cardiac tissue damage by exacerbated
252 inflammation. In addition, we consistently found more profound effects of JUUL Mint on inflammatory

253 cytokine and chemokine gene expression, suggesting that flavors play a significant role in heart
254 inflammation in response to acute lung injury caused by LPS.

255

256 **Chronic JUUL inhalation by inhaled LPS challenge does not alter protein markers of the**
257 **gastrointestinal tract**

258 We showed that JUUL exposure affected the expression of pro-inflammatory cytokines in colonic tissue
259 under homeostatic conditions. Hence, we also assessed whether this effect would be exacerbated in the
260 context of acute lung injury. No greater increases in TNF α , IL-6 or IL-1 β following LPS treatment were
261 observed in mice subjected to 1 of 3 months of JUUL exposure (**Figure 7A-F**).

262

263

264 **Discussion**

265 E-cigarette use has been linked to adverse cardiovascular (35) and immune responses (36, 37). However,
266 little is known about the effects of e-cigarette use on the brain and gastrointestinal system. In this study,
267 we found that mice exposed to flavored JUUL aerosols may induce significant neuroinflammation in the
268 brain (**Figure 8**). The nucleus accumbens in particular was found to have elevated levels of inflammatory
269 markers, including TNF α , IL-1 β and IL-6 in both NAc-core and NAc-shell, and HMGB1-1 and RAGE in
270 the NAc-shell (38). The NAc-core and NAc-shell contribute to the formation of anxious or depressive
271 behaviors in the context of neuroinflammation via NF κ B signaling pathway (39, 40). The NAc-core and
272 NAc-shell are known to control reward-related behaviors through distinct neurocircuitry (41-43). We
273 have previously shown that chronic exposure to ethanol is associated with dysregulation of the
274 glutamatergic system and neuroinflammatory response in the NAc-shell but not in the NAc-core (44, 45).
275 Recently, we found that 3-month exposure to either JUUL Mint or Mango induced dysregulation in
276 glutamatergic system in the NAc-shell but not in the NAc-core (37). Our data further confirms the
277 deleterious effects of JUUL exposure on the nucleus accumbens. On the other hand, the hippocampus, in
278 which learning and memory are essential functions of (40), did not show significant changes in any of the
279 cytokines tested, except for HMGB1. In the particular case of HMGB1 and its receptor RAGE, increased
280 HMGB1 expression has been found to be a marker of neuroinflammatory conditions and may be a
281 predictor of cognitive decline (46).

282
283 Exposure to drugs such as methamphetamine, cocaine and ethanol activate neuroinflammatory pathways
284 that are associated with the release of HMGB1-1 in the striatum and nucleus accumbens, potentially
285 linked to addictive behaviors and drug reward (45, 47). The overall similarity in inflammatory profiles
286 and brain regions between drugs of abuse and that observed in this model of chronic JUUL exposure is
287 certainly cause for concern as it suggests that e-cigarette use may be associated with addictive behaviors
288 (48). Further studies into the overlap of induced neuroinflammatory pathways between drugs of abuse and
289 JUUL is required to better understand these relationships. This includes studies in human subjects to

290 assess the incidence of anxiety and depression in JUUL users. A correlation had previously been observed
291 between vaping and mental health (49). Furthermore, many e-cigarette vapers, including JUUL users, are
292 also cigarette smokers. In some cases, smokers use JUULs as an attempt to help with smoking cessation.
293 However, data thus far demonstrates that e-cigarettes do not increase the rates of successful smoking
294 cessation attempts (14). Indeed, neuroinflammatory effects caused by chronic, daily JUUL exposure may
295 lead to adaptations in neural circuitry that promote addictive behaviors and drug dependence, providing a
296 neurophysiological explanation for the observation that JUUL use does not help with smoking cessation.
297

298 It is well established that high concentrations of nicotine inhalation are toxic to the human body in a
299 variety of ways (50). JUUL pods have been found to have the highest nicotine concentration (up to 10
300 times more) of any of the other cartomizer style e-cigarette or refill fluids (51). Previous studies utilizing
301 continuous systemic delivery of nicotine via implanted pumps concluded that nicotine did not contribute
302 to the development of neuroinflammation. The differences in findings between this study and previous
303 work could be explained by differences in the mode of nicotine delivery, type of nicotine (free-base
304 nicotine and nicotinic salts), inhalant device or other chemicals contained in the vaping aerosols,
305 including vehicle components. Notably, because Mint and Mango effects differed, several of our findings
306 point to a “non-nicotine” chemical flavorant component of the JUUL device that may be driving
307 inflammatory changes in the brain. Recent study into the effects of vaping on the blood brain barrier lends
308 further support to this theory, as pro-inflammatory changes were observed, partly independent of nicotine
309 content (38).

310
311 While the nicotine concentration in JUUL pods is quite high, it does not vary with the JUUL flavor (51).
312 The basis for the variation between the two different JUUL flavored pods tested in our study is most
313 likely due to the differences in chemical flavorants. We observed significantly different inflammatory
314 gene alterations in cardiac and colonic tissue in response to chronic exposure to Mint and Mango JUUL
315 vapor (**Figure 8**). Ethyl maltol concentrations have been shown to be highest in Mango pods (1 mg/ml),

316 while menthol concentrations are highest in cool Mint pods (10 mg/ml)(51). The most remarkable
317 variations we observed were in response to acute lung injury through LPS challenge, where significantly
318 higher levels of cardiac inflammatory genes were seen in mice exposed to Mint relative to Mango and
319 controls. In the brain, inhalation of JUUL Mint aerosols led to higher TNF α and IL-1 β in the NAc-shell
320 relative to JUUL Mango. Mint aerosols are highly similar to menthol aerosols and previous studies have
321 shown greater increases in neuronal nAChR receptors after exposure to nicotine with menthol relative to
322 nicotine exposure alone (52). As a result, we surmise that the flavoring compound menthol in “Cool
323 Mint” may be a factor leading to differences seen in the effects of Mint vs Mango. Overall, these findings
324 suggest that components other than nicotine may contribute to the observed neuroinflammatory changes.
325 Further research is needed to better understand how specific, non-nicotine JUUL components contribute
326 to inflammatory and neuronal effects.

327

328 Collagen expression is a hallmark of fibrosis and has previously been observed in studies involving
329 combustible cigarette smoke (30). However, compared to our prior study with Vape pens (using the nose-
330 only InExpose system by SciReq) where profound increases in collagen deposition were observed across
331 cardiac, hepatic and renal issues (10), we did not find increased fibrosis in these same organs in JUUL
332 exposed mice. This raises questions about the role of different e-cigarette devices, e-liquids and
333 experimental approaches for aerosol exposures and suggests differences in the chemical composition of
334 aerosol and its delivery as potential causes of different biological outcomes. Research in this area is thus
335 complex, as many teams are using a variety of devices and liquids, which may produce different effects
336 on mammalian systems.

337

338 Intensive research has been done on the effect of cigarette smoke on inflammation and the pathogenesis
339 of diseases such as Ulcerative Colitis and Crohn’s Disease, however there are mixed, somewhat
340 inconclusive results when it comes to whether this exposure leads to long-term activation or suppression
341 of inflammatory pathways, and their relation to the likelihood of developing these gastrointestinal

342 afflictions (26). Nicotine specifically has been previously found to decrease the expression of pro-
343 inflammatory cytokines in the colon (53). Here, we saw an increase in pro-inflammatory cytokines in the
344 colon after 1 month of chronic exposure, whereas these same signals were significantly decreased after 3
345 month exposure when compared to the control group (**Figure 8**). Thus, over the course of the 3 months,
346 the body may adapt to these changes and downregulate these markers significantly through some yet
347 unidentified mechanism, pathway, or interaction with the specific components in the JUUL device.
348 Whether this inflammatory adaption is beneficial or detrimental to the overall health of the colon remains
349 to be defined.

350

351 Bacterial pneumonia and acute lung injury are known to cause inflammation systemically and in the heart
352 (31). Indeed, effects of viral infections such as SARS-CoV-2, while originating in the lung, appear to also
353 signal to the heart, where pathological inflammation and cardiac dysfunction are observed (54, 55). The
354 importance of cardiac inflammation in development of heart failure following viral infection, myocardial
355 infarction and non-ischemic cardiac injury has been increasingly appreciated (56). For example, IL-1 β
356 blockade has been shown to diminish adverse cardiac events and heart failure progression (57, 58). We
357 demonstrate here that the hearts of mice subject to chronic JUUL exposure are significantly more sensitive
358 to the effects of LPS delivered to the lung than are Air control mice, as evidenced by enhanced expression
359 of pro-inflammatory cytokines and chemokines including IL-1 β . The observation that there were no
360 significant changes in vagal tone (assessed by heart rate variability) and that the pro-inflammatory
361 enhancement by JUUL exposure was largely confined to JUUL Mint, suggests that this is not due to signals
362 generated by direct nicotine action. While the mechanism by which chronic JUUL exposure predisposes to
363 LPS-induced cardiac inflammation remains to be determined, these findings suggest that chronic JUUL
364 inhalation could lead to systemic changes which sensitize maladaptive inflammatory responses that affect
365 cardiac function.

366

367 Contrary to our initial expectations, we did not find significant changes in autonomic tone or pulmonary
368 function with daily, long-term JUUL aerosol exposure. Our model is limited in that mice are primarily
369 nose breathers and we used whole-body exposure, so it is possible that the extent of e-cigarette aerosol
370 exposure at the level of the alveoli may be lower than in humans due to aerosol deposition within the
371 nasal cavity. Alternatively, our study may be underpowered to detect subtle differences induced by JUUL
372 vaping. However, it is important to mention that this is the first study assessing JUUL devices in a
373 multiorgan fashion. In addition, we found clear effects of JUUL aerosols on inflammatory responses in
374 organs other than the lungs. Thus, the effects of e-cigarette exposure may be greater on organs far
375 removed from the lungs, the first organ to come in contact with aerosols.

376

377

378 **Conclusion**

379 These data indicate that chronic inhalation of chemicals within e-cigarette aerosols leads to identifiable
380 inflammatory changes within multiple organs. JUUL users may unwittingly expose themselves to
381 neurologic, colonic and cardiac inflammatory effects. Further research is needed to better understand the
382 long-lasting effects of vaping.

383

384 **Materials and Methods**

385 **JUUL Exposures**

386 Six to eight week old female C57BL/6 mice were purchased from Envigo. Mice were placed in individual
387 sections of a full-body exposure chamber (Scireq) for 20 minutes daily for 5 days per week, for 4-12
388 weeks. Mice were exposed to either e-cigarette aerosol created from Mango JUUL pods or Mint JUUL
389 pods containing 5% nicotinic salts (59 mg/ml) using the InExpose system (Scireq). Air control mice were
390 placed in an identical chamber for the same amount of time but inhaled room air only. A 3-D printed
391 adapter was created to produce a tight fit for the JUUL device (designed and produced by Vitorino
392 Scientific LLC). A negative pressure of 2L/s was used to activate the e-cigarette for 4 seconds followed
393 by 16 seconds of room air at 2L/s. The final exposure was done 30 minutes prior to harvest. All
394 experiments were conducted with approval of the UCSD Institutional Animal Care and Use Committee
395 (IACUC protocol S16021). All authors complied with the ARRIVE guidelines.

396

397 **LPS Intranasal Challenge**

398 Mice were sedated with isoflurane, held upright and intranasally challenged with LPS (*E.coli* O111:B4;
399 Sigma) at a concentration of 2.5 µg per gram of mouse in 0.9% saline (100 µl). The LPS challenge was
400 given through the left nare to decrease liquid trapping in the nasopharyngeal dead space. Mice were
401 maintained in the upright position until respirations returned to normal. Mice were monitored overnight
402 prior to harvest 24 hours after challenge.

403

404 **Assessment of Pulmonary Function**

405 At the end of 4 and 12 weeks of exposure, prior to harvest, mice were sedated via intraperitoneal (i.p.)
406 injection of ketamine 10mg/ml xylazine 100mg/ml. Mice underwent tracheostomy with 18g metal
407 cannula and were attached to the FlexiVent mouse ventilator (SciReq). Measurements of lung physiology
408 via mechanic scans were obtained at baseline, followed by assessment of physiologic responses to

409 methacholine (MCH) challenge at 0, 6, 12 and 24 mg/ml, including Respiratory Resistance (Rrs) and
410 Elastance (Ers). Pressure Volume (PV) loops were also obtained.

411

412 **Cell Counts and Differential**

413 Bronchoalveolar lavage (BAL) was collected by flushing airways with ice cold 800 ul PBS three times
414 via mouse tracheal cannulation. Samples were pelleted at 3000 rpm for 4 minutes at 4°C. Pellets were
415 resuspended in 1 ml of ice cold PBS, counted with Countess (Life Technologies) for total cells
416 quantification. Later, two dilutions (1:1 and 1:4) of total cells were cytospun onto slides at 800 rpm for 3
417 minutes and then cells were fixed with Giemsa Wright. Slides were de-identified and randomized prior to
418 blinded cell counting; 200 cells from each slide were counted via light microscopy under 40X
419 magnification, and finally percentage of neutrophils was calculated and total amounts of neutrophils
420 extrapolated based on total cell quantification.

421

422 **Histology**

423 Lungs were inflated with Zfix (Anatech ltd) at 25cm H₂O pressure for 18 hours, followed by transfer into
424 75% ethanol prior to paraffin embedding. Lung slices were stained with H&E.

425

426 **Fibrosis Analysis**

427 The right kidney, one lobe of liver, and the base of the heart were then immediately dissected after
428 euthanasia and placed in Z-fix at 4°C. After 48 h, all organs were moved to 75% ethanol and submitted to
429 the University of California, San Diego histology core for paraffin embedding. Collagen was detected in
430 5-µm sections first by Masson's trichrome stain. All histology slides underwent quantification of fibrosis
431 by calculating the mean percent fibrotic area in 15-25 randomly acquired ~20 images using computer-
432 aided morphometry performed using ImageJ. Briefly, using the color threshold with default thresholding
433 method, red threshold color and HSB color space, the total area of tissue in the slide was selected and
434 measured, later the tissue stained for Masson's trichrome blue was also selected and measured prior

435 adjustment of the “Hue” parameter (Saturation Brightness/Value Each colour shade). Then, a percentage
436 of the area stained by Masson’s trichrome blue was determined relative to the total tissue area. All
437 histology slides from the same tissue group were blinded and underwent these computer analyses in an
438 identical fashion. Fibrotic area is presented relative to that of air controls.

439

440 **Isolation of RNA from the murine colonic tissue and qRT-PCR for inflammatory cytokines**

441 RNA was isolated from mouse colon tissues using the Zymo miniprep kit according to the manufacturer's
442 instructions, followed by cDNA synthesis. Quantitative Real-Time PCR was conducted for target genes
443 and normalized to housekeeping gene 18S rRNA. Primer sequences are provided in **Table 1**.

444 **Table 1.**

qPCR (Mouse)	Primers	Forward primer (3'- 5')	Reverse primer (3'- 5')
Mouse 18S		GTAACCCGTTGAACCCCAT	CCATCCAATCGGTAGTAGCG
Mouse IL-6		CCCCAATTTCCAATGCTCTC C	CGCACTAGGTTTGCCGAGTA
Mouse IL-1 β		GAAATGCCACCTTTTGACAG T	CTGGATGCTCTCATCAGGAC A
Mouse TNF-alpha		CCACCACGCTCTTCTGTCTA	AGGGTCTGGGCCATAGAAC T
Mouse IL-8		CCTGCTCTGTCACCGATG	CAGGGCAAAGAACAGGTCA G
Mouse MCP-1		AAGTGCAGAGAGCCAGACG	TCAGTGAGAGTTGGCTGGTG

445

446 **Cardiovascular Physiology Measurements**

447 Heart rate, heart rate variability (HRV) and blood pressure measurements were taken after the last
448 exposure to JUUL aerosol or Air at 1 and 3 months, via the Emka non-invasive ECG Tunnels and the
449 CODA non-invasive blood pressure system. Prior to data collection, mice were acclimated for 20 minutes
450 per day for the last 3 days in the ECG and blood pressure systems. Heart rate variability was determined
451 through time-domain measurements, specifically SDNN and RMSSD. The SDNN is the standard
452 deviation of all normal R-R intervals, providing information on total autonomic variability. The RMSSD
453 is the root mean square of those standard deviations and represents the variability in the short term.

454

455 **Brain tissue harvesting**

456 At the end of the experiments, mice were euthanized by ketamine and xylazine i.p. injection, rapidly
457 decapitated, with their brains removed and stored at -80°C. The cryostat apparatus maintained at -20°C
458 and used to dissect NAc-core, NAc-shell, and HIP, which micropunched stereotaxically. The stereotaxic
459 coordinates for the mice brain (59) was used to isolate the brain regions of interest following visualized
460 landmarks.

461

462 **qRT-PCR**

463 Total RNA from the NAc-core, NAc-shell and HIP of JUUL Mango, JUUL Mint exposed groups, in
464 addition to Air control group. Brain tissue was extracted with TRIzol reagent, using the manufacturer's
465 protocol (Invitrogen, USA). The cDNA was synthesized using the iScript cDNA synthesis kit (Bio-Rad,
466 USA). The mRNA expression level of the brain tissue was detected by qRT-PCR via iQ SYBER green I
467 Supermix (Bio-Rad, USA) and a Bio-Rad RT-PCR instrument system. The thermocycling protocol
468 consisted of 10 min at 95°C, 40 cycles of 15 sec at 95°C, 30 sec at 60°C, and 20 sec at 72°C and
469 completed with a melting curve ranging from 60–95°C to facilitate distinction of specific products. A
470 reaction with primers of TNF α , IL-1 β and IL-6 was performed, the glyceraldehyde-3-phosphate
471 dehydrogenase (GAPDH) gene was used as a housekeeping control. Data were expressed as fold change
472 ($2^{-\Delta\Delta C_T}$) relative to the control group. The primer sequences are listed in **Table 2**.

473

474 **Table 2.**

Targets	Primers	Sequences	References
GAPDH	Forward (Sense)	5'-ATGACATCAAGAAGGTGGTG-3'	(60)
	Reverse (Antisense)	5'-CATACCAGGAAATGAGSCTTG-3'	
IL-1 β	Forward (Sense)	CCAGCTTCAAATCTCACAGCAG	(61)
	Reverse (Antisense)	CTTCTTTGGGTATTGCTTGGGATC	

TNF- α	Forward (Sense)	CACAGAAAGCATGATCCGCGACGT	(61)
	Reverse (Antisense)	CGGCAGAGAGGAGGTTGACTTTCT	
IL-6	Forward (Sense)	TCCAGTTGCCTTCTTGGGAC	(61)
	Reverse (Antisense)	GTACTCCAGAAGACCAGAGG	

475

476

477 **Brain Western Blot**

478 Immunoblot assays were conducted to measure the expression of HMGB1 and RAGE proteins in the
479 NAc core, NAc shell and HIP as described previously (62). Briefly, the samples were homogenized with
480 lysis buffer containing protease and phosphatase inhibitors. The amount of protein in each tissue sample
481 was quantified using detergent compatible protein assay (Bio-Rad, Hercules, CA, USA). Then, 10%
482 polyacrylamide gels used, in which, an equal amount of protein from each sample was loaded. Proteins
483 were then transferred to a PVDF membrane and blocked with 5% fat free milk in Tris-buffered saline
484 with Tween-20 (TBST). Membranes then incubated with appropriate primary antibodies at 4°C
485 (overnight): rabbit anti-HMGB1 (1:1000; Abcam), rabbit anti-RAGE (1:1000; Abcam) and mouse anti-
486 β -tubulin (1:1000; BioLegend; used as a control loading protein). Membranes were then incubated with
487 appropriate secondary antibody (1:5000) for 90 minutes at room temperature. Chemiluminescent
488 reagents (Super Signal West Pico, Pierce Inc.) were incubated with the membranes. The GeneSys
489 imaging system was used and the digitized blot images were developed. Quantification and analysis of
490 the expression of HMGB1, RAGE and β -tubulin were performed using ImageJ software. Air control
491 group data were represented as 100% to assess the change in the expression of the protein of interest as
492 described previously (63).

493

494 **RNA Isolation, cDNA Synthesis and qRT-PCR from Cardiac Tissue**

495 RNA was isolated from samples of cells or tissue homogenized in TRIzol (Invitrogen), with subsequent
496 extraction with chloroform, precipitation of RNA with isopropanol, and washing of RNA pellet twice
497 with 70% ethanol. Synthesis of cDNA from isolated RNA was carried out using the High-Capacity cDNA

498 Reverse Transcription kit with RNase inhibitor (Applied Biosystems). qRT-PCR was carried out using
499 predesigned PrimeTime qPCR Primers (IDT) and TaqMan Universal Master Mix II with UNG (Applied
500 Biosystems), combined with cDNA samples in a 96-well PCR plate and run on a 7500 Fast Real-Time
501 PCR system (Applied Biosystems). The gene expression data acquired was analyzed using the
502 comparative $2^{-\Delta\Delta CT}$ method, with GAPDH expression levels used as the internal control.

503

504 **Cytokine Profiling**

505 Cytokine and chemokine levels were assessed in the BAL with Duo-Set Enzyme-Linked Immunosorbent
506 Assays (R&D Systems Inc., Minneapolis, MN). ELISAs were performed per manufacture's instructions.

507

508 **Statistical Analyses**

509 Analyses were conducted using GraphPad Prism v6.0 or v8.0. Assays with data from more than 2 groups
510 or timepoints were analyzed by ANOVA and are presented as means +/- SEM. Quantification and
511 analysis of Western blot protein levels of HMGB1, RAGE and β -tubulin, and histologic examination of
512 tissue fibrosis, were performed using ImageJ software. The gene expression data acquired by qPCR was
513 analyzed using the comparative $2^{-\Delta\Delta CT}$ method, with GAPDH (brain) and 18S rRNA (colon) expression
514 levels used as the internal control.

515

516

517

518

519

520 **References**

- 521
- 522 1. Shin S, Crotty Alexander LE. Global state of tobacco use: summary from the American
523 Thoracic Society International Conference 2016. *J Thorac Dis.* 2016;8(Suppl 7):S582-5.
- 524 2. Crotty Alexander LE, Shin S, Hwang JH. Inflammatory Diseases of the Lung Induced by
525 Conventional Cigarette Smoke: A Review. *Chest.* 2015;148(5):1307-22.
- 526 3. The Health Consequences of Smoking—50 Years of Progress. In: General TS, editor.
527 2014.
- 528 4. Cahn Z, Siegel M. Electronic cigarettes as a harm reduction strategy for tobacco control:
529 a step forward or a repeat of past mistakes? *J Public Health Policy.* 2011;32(1):16-31.
- 530 5. Crotty Alexander LE, Vyas A, Schraufnagel DE, Malhotra A. Electronic cigarettes: the
531 new face of nicotine delivery and addiction. *J Thorac Dis.* 2015;7(8):E248-51.
- 532 6. Huang J, Duan Z, Kwok J, Binns S, Vera LE, Kim Y, et al. Vaping versus JUULing: how
533 the extraordinary growth and marketing of JUUL transformed the US retail e-cigarette market.
534 *Tob Control.* 2019;28(2):146-51.
- 535 7. Tsai M, Byun MK, Shin J, Crotty Alexander LE. Effects of e-cigarettes and vaping
536 devices on cardiac and pulmonary physiology. *J Physiol.* 2020.
- 537 8. Bozier J, Chivers EK, Chapman DG, Larcombe AN, Bastian NA, Masso-Silva JA, et al.
538 The Evolving Landscape of e-Cigarettes: A Systematic Review of Recent Evidence. *Chest.*
539 2020;157(5):1362-90.
- 540 9. Craver R. Juul ends 2018 with 76 percent market share. *Winston-Salem Journal.* 2019 Jan
541 8, 2019.
- 542 10. Crotty Alexander LE, Drummond CA, Hepokoski M, Mathew D, Moshensky A,
543 Willeford A, et al. Chronic inhalation of e-cigarette vapor containing nicotine disrupts airway
544 barrier function and induces systemic inflammation and multiorgan fibrosis in mice. *Am J*
545 *Physiol Regul Integr Comp Physiol.* 2018;314(6):R834-R47.
- 546 11. Garcia-Arcos I, Geraghty P, Baumlin N, Campos M, Dabo AJ, Jundi B, et al. Chronic
547 electronic cigarette exposure in mice induces features of COPD in a nicotine-dependent manner.
548 *Thorax.* 2016;71(12):1119-29.
- 549 12. Tang MS, Wu XR, Lee HW, Xia Y, Deng FM, Moreira AL, et al. Electronic-cigarette
550 smoke induces lung adenocarcinoma and bladder urothelial hyperplasia in mice. *Proc Natl Acad*
551 *Sci U S A.* 2019;116(43):21727-31.
- 552 13. Madison MC, Landers CT, Gu BH, Chang CY, Tung HY, You R, et al. Electronic
553 cigarettes disrupt lung lipid homeostasis and innate immunity independent of nicotine. *J Clin*
554 *Invest.* 2019;129(10):4290-304.
- 555 14. Alasmari F, Crotty Alexander LE, Nelson JA, Schiefer IT, Breen E, Drummond CA, et
556 al. Effects of chronic inhalation of electronic cigarettes containing nicotine on glial glutamate
557 transporters and alpha-7 nicotinic acetylcholine receptor in female CD-1 mice. *Prog*
558 *Neuropsychopharmacol Biol Psychiatry.* 2017;77:1-8.
- 559 15. Linker KE, Elabd MG, Tawadrous P, Cano M, Green KN, Wood MA, et al. Microglial
560 activation increases cocaine self-administration following adolescent nicotine exposure. *Nat*
561 *Commun.* 2020;11(1):306.
- 562 16. Lau WK, Mak JC, Chan KH, Law AC. Cigarette smoke-induced cerebral cortical
563 interleukin-6 elevation is not mediated through oxidative stress. *Neurotox Res.* 2012;22(2):170-
564 6.

- 565 17. Bradford ST, Stamatovic SM, Dondeti RS, Keep RF, Andjelkovic AV. Nicotine
566 aggravates the brain postischemic inflammatory response. *Am J Physiol Heart Circ Physiol*.
567 2011;300(4):H1518-29.
- 568 18. Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders. *Nat Rev Neurosci*.
569 2013;14(9):609-25.
- 570 19. Le Y, Wang Y, Zhou L, Xiong J, Tian J, Yang X, et al. Cigarette smoke-induced
571 HMGB1 translocation and release contribute to migration and NF-kappaB activation through
572 inducing autophagy in lung macrophages. *J Cell Mol Med*. 2020;24(2):1319-31.
- 573 20. Robinson AB, Stogsdill JA, Lewis JB, Wood TT, Reynolds PR. RAGE and tobacco
574 smoke: insights into modeling chronic obstructive pulmonary disease. *Front Physiol*. 2012;3:301.
- 575 21. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, Criqui M, et al.
576 Markers of inflammation and cardiovascular disease: application to clinical and public health
577 practice: A statement for healthcare professionals from the Centers for Disease Control and
578 Prevention and the American Heart Association. *Circulation*. 2003;107(3):499-511.
- 579 22. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, et al.
580 Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial
581 infarction: the Framingham Heart Study. *Circulation*. 2003;107(11):1486-91.
- 582 23. Liu T, Song D, Dong J, Zhu P, Liu J, Liu W, et al. Current Understanding of the
583 Pathophysiology of Myocardial Fibrosis and Its Quantitative Assessment in Heart Failure. *Front*
584 *Physiol*. 2017;8:238.
- 585 24. Ma ZG, Yuan YP, Wu HM, Zhang X, Tang QZ. Cardiac fibrosis: new insights into the
586 pathogenesis. *Int J Biol Sci*. 2018;14(12):1645-57.
- 587 25. Bennett JM, Reeves G, Billman GE, Sturmberg JP. Inflammation-Nature's Way to
588 Efficiently Respond to All Types of Challenges: Implications for Understanding and Managing
589 "the Epidemic" of Chronic Diseases. *Front Med (Lausanne)*. 2018;5:316.
- 590 26. Verschuere S, De Smet R, Allais L, Cuvelier CA. The effect of smoking on intestinal
591 inflammation: what can be learned from animal models? *J Crohns Colitis*. 2012;6(1):1-12.
- 592 27. Berkowitz L, Schultz BM, Salazar GA, Pardo-Roa C, Sebastian VP, Alvarez-Lobos MM,
593 et al. Impact of Cigarette Smoking on the Gastrointestinal Tract Inflammation: Opposing Effects
594 in Crohn's Disease and Ulcerative Colitis. *Front Immunol*. 2018;9:74.
- 595 28. Sharma A LJ, Fonseca AG, Moshensky A, Kothari T, Sayed IM, Ibeawuchi SR,
596 Pranadinata RF., Ear J, Sahoo D, Crotty-Alexander L, Ghosh P, Das S. E-cigarettes compromise
597 the gut barrier, trigger inflammation. 2020.
- 598 29. Glynos C, Bibli SI, Katsaounou P, Pavlidou A, Magkou C, Karavana V, et al.
599 Comparison of the effects of e-cigarette vapor with cigarette smoke on lung function and
600 inflammation in mice. *Am J Physiol Lung Cell Mol Physiol*. 2018;315(5):L662-L72.
- 601 30. Drummond CA, Crotty Alexander LE, Haller ST, Fan X, Xie JX, Kennedy DJ, et al.
602 Cigarette smoking causes epigenetic changes associated with cardiorenal fibrosis. *Physiol*
603 *Genomics*. 2016;48(12):950-60.
- 604 31. Morris A. Heart-lung interaction via infection. *Ann Am Thorac Soc*. 2014;11 Suppl
605 1:S52-6.
- 606 32. Feldman C, Normark S, Henriques-Normark B, Anderson R. Pathogenesis and
607 prevention of risk of cardiovascular events in patients with pneumococcal community-acquired
608 pneumonia. *J Intern Med*. 2019;285(6):635-52.
- 609 33. Kondo T, Nakano Y, Adachi S, Murohara T. Effects of Tobacco Smoking on
610 Cardiovascular Disease. *Circ J*. 2019;83(10):1980-5.

- 611 34. Osei AD, Mirbolouk M, Orimoloye OA, Dzaye O, Uddin SMI, Benjamin EJ, et al.
612 Association Between E-Cigarette Use and Cardiovascular Disease Among Never and Current
613 Combustible-Cigarette Smokers. *Am J Med.* 2019;132(8):949-54 e2.
- 614 35. Lee HW, Park SH, Weng MW, Wang HT, Huang WC, Lepor H, et al. E-cigarette smoke
615 damages DNA and reduces repair activity in mouse lung, heart, and bladder as well as in human
616 lung and bladder cells. *Proc Natl Acad Sci U S A.* 2018;115(7):E1560-E9.
- 617 36. Corriden R, Moshensky A, Bojanowski CM, Meier A, Chien J, Nelson RK, et al. E-
618 cigarette use increases susceptibility to bacterial infection by impairment of human neutrophil
619 chemotaxis, phagocytosis, and NET formation. *Am J Physiol Cell Physiol.* 2020;318(1):C205-
620 C14.
- 621 37. Hwang JH, Lyes M, Sladewski K, Enany S, McEachern E, Mathew DP, et al. Electronic
622 cigarette inhalation alters innate immunity and airway cytokines while increasing the virulence
623 of colonizing bacteria. *J Mol Med (Berl).* 2016;94(6):667-79.
- 624 38. Heldt NA, Seliga A, Winfield M, Gajghate S, Reichenbach N, Yu X, et al. Electronic
625 cigarette exposure disrupts blood-brain barrier integrity and promotes neuroinflammation. *Brain*
626 *Behav Immun.* 2020;88:363-80.
- 627 39. Mavridis I. [The role of the nucleus accumbens in psychiatric disorders]. *Psychiatriki.*
628 2015;25(4):282-94.
- 629 40. Decarie-Spain L, Sharma S, Hryhorczuk C, Issa-Garcia V, Barker PA, Arbour N, et al.
630 Nucleus accumbens inflammation mediates anxiodepressive behavior and compulsive sucrose
631 seeking elicited by saturated dietary fat. *Mol Metab.* 2018;10:1-13.
- 632 41. Augur IF, Wyckoff AR, Aston-Jones G, Kalivas PW, Peters J. Chemogenetic Activation
633 of an Extinction Neural Circuit Reduces Cue-Induced Reinstatement of Cocaine Seeking. *J*
634 *Neurosci.* 2016;36(39):10174-80.
- 635 42. Keistler C, Barker JM, Taylor JR. Infralimbic prefrontal cortex interacts with nucleus
636 accumbens shell to unmask expression of outcome-selective Pavlovian-to-instrumental transfer.
637 *Learn Mem.* 2015;22(10):509-13.
- 638 43. Stefanik MT, Kupchik YM, Kalivas PW. Optogenetic inhibition of cortical afferents in
639 the nucleus accumbens simultaneously prevents cue-induced transient synaptic potentiation and
640 cocaine-seeking behavior. *Brain Struct Funct.* 2016;221(3):1681-9.
- 641 44. Alhaddad H, Alasmari F, Alhamadani B, Wong W, Bell RL, Sari Y. Effects of chronic
642 ethanol consumption on the expression of GLT-1 and neuroplasticity-related proteins in the
643 nucleus accumbens of alcohol-preferring rats. *Brain Res Bull.* 2020;165:272-80.
- 644 45. Alasmari F, Alhaddad H, Wong W, Bell RL, Sari Y. Ampicillin/Sulbactam Treatment
645 Modulates NMDA Receptor NR2B Subunit and Attenuates Neuroinflammation and Alcohol
646 Intake in Male High Alcohol Drinking Rats. *Biomolecules.* 2020;10(7).
- 647 46. Paudel YN, Shaikh MF, Chakraborti A, Kumari Y, Aledo-Serrano A, Aleksovska K, et
648 al. HMGB1: A Common Biomarker and Potential Target for TBI, Neuroinflammation, Epilepsy,
649 and Cognitive Dysfunction. *Front Neurosci.* 2018;12:628.
- 650 47. Gao SQ, Zhang H, He JG, Zheng HL, Zhang PW, Xu JF, et al. Neuronal HMGB1 in
651 nucleus accumbens regulates cocaine reward memory. *Addict Biol.* 2020;25(2):e12739.
- 652 48. Vogel EA, Prochaska JJ, Rubinstein ML. Measuring e-cigarette addiction among
653 adolescents. *Tob Control.* 2020;29(3):258-62.
- 654 49. Obisesan OH, Mirbolouk M, Osei AD, Orimoloye OA, Uddin SMI, Dzaye O, et al.
655 Association Between e-Cigarette Use and Depression in the Behavioral Risk Factor Surveillance
656 System, 2016-2017. *JAMA Netw Open.* 2019;2(12):e1916800.

- 657 50. Mishra A, Chaturvedi P, Datta S, Sinukumar S, Joshi P, Garg A. Harmful effects of
658 nicotine. *Indian J Med Paediatr Oncol*. 2015;36(1):24-31.
- 659 51. Omaiye EE, McWhirter KJ, Luo W, Pankow JF, Talbot P. High-Nicotine Electronic
660 Cigarette Products: Toxicity of JUUL Fluids and Aerosols Correlates Strongly with Nicotine and
661 Some Flavor Chemical Concentrations. *Chem Res Toxicol*. 2019;32(6):1058-69.
- 662 52. Henderson BJ, Wall TR, Henley BM, Kim CH, McKinney S, Lester HA. Menthol
663 Enhances Nicotine Reward-Related Behavior by Potentiating Nicotine-Induced Changes in
664 nAChR Function, nAChR Upregulation, and DA Neuron Excitability.
665 *Neuropsychopharmacology*. 2017;42(12):2285-91.
- 666 53. Van Dijk JP, Madretsma GS, Keuskamp ZJ, Zijlstra FJ. Nicotine inhibits cytokine
667 synthesis by mouse colonic mucosa. *Eur J Pharmacol*. 1995;278(1):R11-2.
- 668 54. Lindner D, Fitzek A, Brauninger H, Aleshcheva G, Edler C, Meissner K, et al.
669 Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases.
670 *JAMA Cardiol*. 2020;5(11):1281-5.
- 671 55. Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular
672 disease: from basic mechanisms to clinical perspectives. *Nat Rev Cardiol*. 2020;17(9):543-58.
- 673 56. Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Reappraising the role of
674 inflammation in heart failure. *Nat Rev Cardiol*. 2020;17(5):269-85.
- 675 57. Everett BM, Cornel JH, Lainscak M, Anker SD, Abbate A, Thuren T, et al. Anti-
676 Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart
677 Failure. *Circulation*. 2019;139(10):1289-99.
- 678 58. Abbate A, Trankle CR, Buckley LF, Lipinski MJ, Appleton D, Kadariya D, et al.
679 Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-
680 Elevation Myocardial Infarction. *J Am Heart Assoc*. 2020;9(5):e014941.
- 681 59. Paxinos G, Halliday G, Watson C, Kassem MS. Atlas of the developing mouse brain:
682 Academic press; 2020.
- 683 60. Sandhir R, Onyszchuk G, Berman NE. Exacerbated glial response in the aged mouse
684 hippocampus following controlled cortical impact injury. *Exp Neurol*. 2008;213(2):372-80.
- 685 61. Kawane K, Tanaka H, Kitahara Y, Shimaoka S, Nagata S. Cytokine-dependent but
686 acquired immunity-independent arthritis caused by DNA escaped from degradation. *Proc Natl*
687 *Acad Sci U S A*. 2010;107(45):19432-7.
- 688 62. Alhaddad H, Kim NT, Aal-Aaboda M, Althobaiti YS, Leighton J, Boddu SH, et al.
689 Effects of MS-153 on chronic ethanol consumption and GLT1 modulation of glutamate levels in
690 male alcohol-preferring rats. *Front Behav Neurosci*. 2014;8:366.
- 691 63. Alhaddad H, Das SC, Sari Y. Effects of ceftriaxone on ethanol intake: a possible role for
692 xCT and GLT-1 isoforms modulation of glutamate levels in P rats. *Psychopharmacology (Berl)*.
693 2014;231(20):4049-57.

694
695
696

697 **Acknowledgments**

698 **Funding:** This work was supported by grants from the National Institutes of Health (NIH), including NIH
699 R01HL147326 (LCA) R01HL145459 (JHB), T32HL007444 (CB), American Heart Association
700 beginning grant-in-aid 16BGIA27790079 (LCA) Postdoctoral Award 19POST34430051 (CB), UCSD
701 grant RS169R (LCA), ATS Foundation Award for Outstanding Early Career Investigators (LCA), VA
702 Merit Award, 1I01BX004767 (LCA), as well as Tobacco-Related Disease Research Program grants
703 T30IP0965 (LCA), 26IP-0040 (JHB), and 28IP-0024 (SD).


704 **Author contributions:** Conception and design of the experiments: AM, CB, HA, JS, JAMS, AS, DA,
705 SD, ZS, YS, JHB and LCA. Acquisition of data: AM, CB, HA, JS, IA, DG, AS, SM, AJ, SN, JP, SP, KP
706 and RAK. Analysis and interpretation of data: AM, CB, HA, JAMS, AS, DA, SD, MB, ZS, YS, JHB and
707 LCA. Manuscript composition: AM, CB, HA, JAMS, IA, DG, SD, YS, JHB and LCA. All authors
708 reviewed, contributed to, and approved the manuscript.

709 **Competing interests:** The authors have no competing interests.

710 **Data and materials availability:** Please contact Dr. Crotty Alexander.


711

712 **Figures and Figure Legends**



713
 714 **Figure 1. Chronic JUUL use leads to an increase of pro-inflammatory cytokines in different regions**
 715 **of the brain.** Brains were harvested at the end point and the regions for NAc-core, NAc-shell and
 716 Hippocampus were sectioned. Later, the RNA was extracted and qPCR was performed to quantify the
 717 expression of TNF α , IL-1 β , IL-6. TNF α expression is shown from NAc-core at A) 1 month and B) 3
 718 months, from NAc-shell at C) 1 month and D) 3 months, and from Hippocampus at E) 1 month and F) 3
 719 months. IL-1 β expression is shown from NAc-core at G) 1 month and H) 3 months, from NAc-shell at I)
 720 1 month and J) 3 months, and from Hippocampus at K) 1 month and L) 3 months. IL-6 expression is
 721 shown from NAc-core at M) 1 month and N) 3 months, from NAc-shell at O) 1 month and P) 3 months,
 722 and from Hippocampus at Q) 1 month and R) 3 months. Data are presented as individual data points \pm
 723 SEM with n=5-6 mice per group. * p <0.05, ** p <0.01, *** p <0.001 and **** p <0.0001.

724
 725
 726




727

728 **Figure 2. Chronic JUUL use leads to an increase of inflammatory mediators HMGB1 and RAGE.**

729 Brains were harvested at the end point and the regions for NAc-core, NAc-shell and Hippocampus were
 730 sectioned. Later, protein was extracted and Western Blot was performed to quantify the expression of
 731 HMGB1-1 and RAGE. HMGB1-1 relative protein level are shown from NAc-core at A) 1 month and B)
 732 3 months, from NAc-shell at C) 1 month and D) 3 months, and from Hippocampus at E) 1 month and F) 3
 733 months. RAGE protein levels are shown from NAc-core at G) 1 month and H) 3 months, from NAc-shell
 734 at I) 1 month and J) 3 months, and from Hippocampus at K) 1 month and L) 3 months. Changes in
 735 proteins levels are relative to Air controls. Data are presented as individual data points \pm SEM with n=5-6
 736 mice per group. * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$.

737



738

739 **Figure 3. Chronic inhalation of JUUL aerosols alters inflammatory and fibrosis associated gene**

740 **expression in cardiac tissue.** Hearts were harvested, and RNA was extracted from the left ventricle and

741 qPCR was performed to quantify the gene expression of different cytokines, chemokines and fibrosis-

742 associated genes. Cytokines include TNF α at A) 1 month and B) 3 months, IL-1 β at C) 1 month and D) 3

743 months, IL-6 at E) 1 month and F) 3 months, and IL-18 at G) 1 month and H) 3 months. Chemokines

744 include CCL2 at I) 1 month and J) 3 months, CCL3 at K) 1 month and L) 3 months, CXCL1 at M) 1

745 month and N) 3 months, and CXCL2 at O) 1 month and P) 3 months. Fibrosis-associated genes include

746 Col1a1 at Q) 1 month and R) 3 months, Col3a1 at S) 1 month and T) 3 months, Postn at U) 1 month and

747 V) 3 months, and TLR4 at W) 1 month and X) 3 months. Changes in expression levels are relative to Air


748 controls. Data are presented as individual data points \pm SEM with n=5-11 mice per group. * $p < 0.05$ and

749 ** $p < 0.01$.

750

751

752



753

754 **Figure 4. Chronic JUUL aerosol inhalation alters pro-inflammatory markers in colon.** Inflammation

755 was assessed in the colon at 1 and 3 months. Panels show inflammation markers in the colon in TNF α A)

756 1 month and B) 3 months, IL-6 at C) 1 month and D) 3 months, IL-1 β at E) 1 month and F) 3 months, IL-

757 8 G) and H), and CCL2 I) 1 month and J) 3 months. Data for inflammation markers is presented as

758 individual data points \pm SEM. * $p < 0.01$ and ** $p < 0.001$.

759

760

761


762

763

764

765

766



767

768 **Figure 5. JUUL exposure alters airway inflammatory responses in the setting of inhaled LPS**

769 **challenge.** BAL was harvested at the endpoints, and cytokines and chemokines were quantified by

770 ELISA. CCL2 at A) 1 month, and B) 3 months, KC at C) 1 month and D) 3 months, MIP2 at E) 1 month

771 and F) 3 month, RANTES at G) 1 month and H) 3 months, TNF α at I) 1 month and J) 3 months, IL-1 β at

772 K) 1 month and L) 3 months, IL-6 at M) 1 month and N) 3 months. Data are presented as individual data


773 points \pm SEM with n=5-11 mice per group. ** p <0.01 and **** p <0.0001.

774

775

776

777



778

779 **Figure 6. Cardiac inflammation induced by inhaled LPS challenge is increased in the setting of**

780 **chronic JUUL aerosol inhalation.** Hearts were harvested, and RNA was extracted from the left ventricle

781 and qPCR was performed to quantify the gene expression of different cytokines, chemokines and fibrosis-

782 associated genes. Cytokines include TNF α at A) 1 month and B) 3 months, IL-1 β at C) 1 month and D) 3

783 months, IL-6 at E) 1 month and F) 3 months, and IL-18 at G) 1 month and H) 3 months. Chemokines

784 include CCL2 at I) 1 month and J) 3 months, CCL3 at K) 1 month and L) 3 months, CXCL1 at M) 1

785 month and N) 3 months, and CXCL2 at O) 1 month and P) 3 months. Fibrosis-associated genes include


786 Col1a1 at Q) 1 month and R) 3 months, Col3a1 at S) 1 month and T) 3 months, Postn at U) 1 month and

787 V) 3 months, and TLR4 at W) 1 month and X) 3 months. Changes in expression levels are relative to Air

788 controls. Data are presented as individual data points \pm SEM with n=5-11 mice per group. * p <0.05,

789 ** p <0.01, *** p <0.001 and **** p <0.0001.

790



791

792

793 **Figure 7. Chronic JUUL inhalation does not alter inflammatory markers in the setting of by**
794 **inhaled LPS challenge in the gastrointestinal tract.** Inflammation was assessed in the colon at 1 and 3


795 months. Panels show inflammation markers in the colon in TNF A) 1 month and B) 3 months, IL-6 at C)

796 1 month and D) 3 months, IL-1 β at E) 1 month and F) 3 months. Data for inflammation markers are

797 presented as individual data points \pm SEM.

798

799



800

801 **Figure 8. Overview of JUUL aerosol induced inflammatory changes across organs.**